Shots:
- The two companies collaborated to discover and develop novel therapeutics interfering with the disease-causing transcriptional programs in cancer and other diseases. Quantro intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts
- Quantro will exploit its functional-genetic and transcriptomic technologies addressing the undruggable targets while Evotec will provide its hit identification services for Quantro’s anti-tumor projects
- Additionally, Evotec joins Boehringer Ingelheim Venture Fund as seed investor in Quantro and acquired equal minority stakes in Quantro
Click here to read full press release/ article | Ref: Evotec | Image: Evotec
